This company has been acquired
Sierra Oncology Management
Management criteria checks 4/4
Key information
Stephen Dilly
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 29.6% |
| CEO tenure | 2.1yrs |
| CEO ownership | n/a |
| Management average tenure | 2yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2022 | n/a | n/a | -US$103m |
| Dec 31 2021 | US$2m | US$627k | -US$95m |
| Sep 30 2021 | n/a | n/a | -US$87m |
| Jun 30 2021 | n/a | n/a | -US$73m |
| Mar 31 2021 | n/a | n/a | -US$69m |
| Dec 31 2020 | US$8m | US$350k | -US$81m |
Compensation vs Market: Stephen's total compensation ($USD2.12M) is below average for companies of similar size in the US market ($USD5.53M).
Compensation vs Earnings: Stephen's compensation has been consistent with company performance over the past year.
CEO
Stephen Dilly (62 yo)
2.1yrs
Tenure
US$2,115,229
Compensation
Dr. Stephen George Dilly, M.B.B.S, Ph D., serves as Director at ImmunoMolecular Therapeutics, Inc since February 2020. Dr. Dilly served as Director at DNAtrix, Inc. since 2019 until 2022 and served as its...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$2.12m | no data | |
| Chief Financial Officer | 7.4yrs | US$1.00m | 0% $ 0 | |
| Chief Medical Officer | 7.1yrs | US$1.13m | 0% $ 0 | |
| General Counsel | 2yrs | no data | no data | |
| Chief Regulatory & Technical Operations Officer | 1.9yrs | no data | no data | |
| Chief Business Officer | 1.9yrs | no data | no data |
2.0yrs
Average Tenure
53.5yo
Average Age
Experienced Management: SRRA's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$2.12m | no data | |
| Independent Chairman | 7.2yrs | US$164.69k | 0.020% $ 275.0k | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Independent Director | 6.3yrs | US$132.93k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.7yrs | US$73.43k | 0% $ 0 | |
| Member of Scientific Advisory Board | 15.8yrs | no data | no data | |
| Member of DDR Advisory Committee | 4.9yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of DDR Advisory Committee | 4.9yrs | no data | no data | |
| Member of DDR Advisory Committee | 4.9yrs | no data | no data | |
| Member of DDR Advisory Committee | 4.9yrs | no data | no data |
4.9yrs
Average Tenure
64yo
Average Age
Experienced Board: SRRA's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/05 06:14 |
| End of Day Share Price | 2022/06/30 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sierra Oncology, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lut Ming Cheng | Cantor Fitzgerald & Co. |
| Maxim Jacobs | Edison Investment Research |
| Joseph Pantginis | H.C. Wainwright & Co. |